Toronto General Hospital

Running trials

• Not yet recruiting

  A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)

  NCT07237282· Phase 1· University of Alberta· Source

• Not yet recruiting

  Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes

  NCT07902726· Phase 2· University Health Network, Toronto· Source

• Not yet recruiting

  Prospective AI-SC Trial

  NCT07927153· University Health Network, Toronto· Source

• Recruiting

  Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

  NCT07654283· Phase 2· AusperBio Therapeutics Inc.· Source

• Recruiting

  Heart Rate VAriability as a MaRker for tItrATing hIgh flOw Nasal Cannula Therapy

  NCT07518862· University Health Network, Toronto· Source

• Recruiting

  JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year

  NCT06930521· Women's College Hospital· Source

• Active, not recruiting

  AI-SC Multi-center Study

  NCT07885007· University Health Network, Toronto· Source

• Enrolling by invitation

  Digital Education in Colorectal Cancer Patients

  NCT07686133· University Health Network, Toronto· Source

• Recruiting

  A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor

  NCT07187401· Phase 1/2· Regeneron Pharmaceuticals· Source

• Not yet recruiting

  Sustained Mood Improvement With Laughing Gas Exposure

  NCT07262008· Phase 3· Women's College Hospital· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Recruiting

  Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

  NCT07223593· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

  NCT06957366· McMaster University· Source

• Recruiting

  An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

  NCT06832410· Phase 3· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  Prevail Global Study

  NCT06535854· Medtronic Vascular· Source

• Recruiting

  Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

  NCT06725121· Phase 1/2· University Health Network, Toronto· Source

• Recruiting

  An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

  NCT06693336· Phase 2· ToLymph Inc.· Source

• Recruiting

  Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

  NCT06217302· Phase 3· Alessandro Doria· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis

  NCT06558279· Phase 3· argenx· Source

• Recruiting

  meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

  NCT05715814· Phase 3· University Health Network, Toronto· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  EASE-SOT Pilot Study

  NCT06396702· University Health Network, Toronto· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

  NCT06480500· Phase 2· University Health Network, Toronto· Source

• Recruiting

  The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

  NCT05938712· Phase 2· University Health Network, Toronto· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Recruiting

  Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

  NCT05955924· Phase 3· Women's College Hospital· Source

• Recruiting

  Comparing Menghini-type Needle and Franseen-type Needle in EBUS-TBNA for Sarcoidosis

  NCT06220526· University Health Network, Toronto· Source

• Recruiting

  A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV

  NCT05495906· Phase 4· University of British Columbia· Source

• Active, not recruiting

  Online Prehabilitation for Patients Awaiting Liver Transplantation

  NCT05899231· University of Alberta· Source

• Recruiting

  The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

  NCT05427370· Sunnybrook Health Sciences Centre· Source

• Active, not recruiting

  A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

  NCT05791201· Phase 1/2· Vertex Pharmaceuticals Incorporated· Source

• Recruiting

  Type 1 Diabetes Virtual Self-management Education and Support

  NCT05756829· Unity Health Toronto· Source

• Active, not recruiting

  Symptom Management in Patients on Dialysis

  NCT05515991· University Health Network, Toronto· Source

• Recruiting

  Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  NCT04124120· Weill Medical College of Cornell University· Source

• Active, not recruiting

  TrEatment Approach in the Multimodal Era Registry

  NCT05629052· International CTEPH Association· Source

• Active, not recruiting

  A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

  NCT05766501· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

  NCT05744921· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

  NCT05631093· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

  NCT05478304· AtriCure, Inc.· Source

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Semaglutide vs Sitagliptin

  NCT05195944· Phase 4· University Health Network, Toronto· Source

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· United Therapeutics· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

  NCT05500222· Phase 3· Madrigal Pharmaceuticals, Inc.· Source

• Recruiting

  MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)

  NCT05487612· Aristotle University Of Thessaloniki· Source

• Active, not recruiting

  Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  NCT05069558· Occlutech International AB· Source

• Recruiting

  Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II

  NCT05102019· Shockwave Medical, Inc.· Source

• Active, not recruiting

  A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

  NCT05071300· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

  NCT05070858· Phase 3· Regeneron Pharmaceuticals· Source

Showing 50 of 79.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease6 recruiting
• Type 1 diabetes5 recruiting
• Heart failure4 recruiting
• Lung cancer3 recruiting
• Type 2 diabetes3 recruiting
• Aortic aneurysm2 recruiting
• Atrial fibrillation2 recruiting
• Chronic kidney disease2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Liver cirrhosis2 recruiting
• Peripheral artery disease2 recruiting
• Sarcoidosis2 recruiting
• Amyloidosis1 recruiting
• Aortic stenosis1 recruiting
• Colorectal cancer1 recruiting
• Congenital heart disease1 recruiting
• Depression1 recruiting
• Epilepsy1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Hepatitis B1 recruiting
• Hepatitis C1 recruiting
• HIV1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Myasthenia gravis1 recruiting
• Primary biliary cholangitis1 recruiting
• Sickle cell disease1 recruiting
• Stroke1 recruiting
• Thalassaemia1 recruiting

Closed trials

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

  NCT06465186· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

  NCT06247735· Phase 2· Kowa Research Institute, Inc.· Source

• Completed

  Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

  NCT05861453· Phase 2· Afimmune· Source

• Terminated

  A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

  NCT06032546· Phase 2· AbbVie· Source

• Completed

  Acorai Machine Learning Generalization (MLG) Study

  NCT05835024· Acorai AB· Source

• Completed

  A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

  NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

  NCT05536804· Phase 2· Eli Lilly and Company· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· The George Institute· Source

• Completed

  Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria

  NCT05570305· Phase 2· University Medical Center Groningen· Source

• Completed

  Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression

  NCT05339074· Phase 2· Joshua Rosenblat· Source

• Completed

  A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

  NCT05133531· Phase 3· Regeneron Pharmaceuticals· Source

• Completed

  Ketamine for Treatment-Resistant Bipolar Disorder

  NCT05004896· Phase 2· Joshua Rosenblat· Source

• Completed

  An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants

  NCT05275023· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)

  NCT05033314· Phase 3· University Health Network, Toronto· Source

• Completed

  PrEP and Alcohol - Enhancing HIV Pre-Exposure Prophylaxis (PrEP)

  NCT05097430· Centre for Addiction and Mental Health· Source

• Completed

  Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

  NCT05027074· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source

• Completed

  A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

  NCT04585789· Phase 2· Janssen Research & Development, LLC· Source

• Terminated

  HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

  NCT04684914· Phase 2· Altimmune, Inc.· Source

• Completed

  A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

  NCT04439539· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source

• Completed

  Nasal High Flow Therapy in Surgical Patients with Unrecognized Obstructive Sleep Apnea

  NCT03964376· University Health Network, Toronto· Source

• Completed

  A Wearable and a Self-management Application for Chronic Obstructive Pulmonary Disease (COPD) Patients at Home

  NCT03857061· University Health Network, Toronto· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection

  NCT03575910· University of British Columbia· Source

• Completed

  The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic, Severe Aortic Stenosis

  NCT03471065· Edwards Lifesciences· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

  NCT00673842· Phase 3· University of Calgary· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer79 works · 1 trial
• Primary biliary cholangitis27 works · 4 trials
• Congenital heart disease14 works · 2 trials
• Hypertrophic cardiomyopathy9 works · 1 trial
• Hepatitis B8 works · 5 trials
• Myasthenia gravis7 works · 3 trials